Cargando…

A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy

The aim of this study was to determine the predictive and prognostic value of epidermal growth factor receptor (EGFR) expression in rectal cancers treated with preoperative high-dose rate brachytherapy and in mismatch-repair (MMR)-proficient colorectal cancers (CRCs), respectively. We validate the u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zlobec, I, Vuong, T, Hayashi, S, Haegert, D, Tornillo, L, Terracciano, L, Lugli, A, Jass, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360062/ https://www.ncbi.nlm.nih.gov/pubmed/17311026 http://dx.doi.org/10.1038/sj.bjc.6603619

Ejemplares similares

Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy
por: Zlobec, I, et al.
Publicado: (2008)

Two-marker protein profile predicts poor prognosis in patients with early rectal cancer
por: Zlobec, I, et al.
Publicado: (2008)

Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer
por: Lugli, A, et al.
Publicado: (2010)

Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients
por: Zlobec, I, et al.
Publicado: (2014)

CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer
por: Lugli, A, et al.
Publicado: (2009)

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers
por: Went, P, et al.
Publicado: (2006)

Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer
por: Koelzer, V H, et al.
Publicado: (2013)

Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer
por: Galván, J A, et al.
Publicado: (2015)

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?
por: Paliga, A, et al.
Publicado: (2012)

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients
por: Ruiz, M I Galleges, et al.
Publicado: (2009)

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
por: Bengala, C, et al.
Publicado: (2010)

The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients
por: Krenn-Pilko, S, et al.
Publicado: (2014)

Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours
por: Caiazza, F, et al.
Publicado: (2011)

Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer
por: Ettl, T, et al.
Publicado: (2012)

Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients
por: Szkandera, J, et al.
Publicado: (2013)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
por: Rego, R L, et al.
Publicado: (2010)

Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma
por: Chang, Y, et al.
Publicado: (2015)

Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy
por: Jia, Y, et al.
Publicado: (2014)

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
por: de Graeff, P, et al.
Publicado: (2009)

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
por: Pichler, M, et al.
Publicado: (2012)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions
por: Terry, G, et al.
Publicado: (2007)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Targeting EGFR and PI3K pathways in ovarian cancer
por: Glaysher, S, et al.
Publicado: (2013)

Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma
por: Baldan, V, et al.
Publicado: (2015)

HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study
por: Attallah, A M, et al.
Publicado: (2013)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways
por: Nabeshima, A, et al.
Publicado: (2015)

Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands
por: Lujan, B, et al.
Publicado: (2010)

Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival
por: Cummings, M, et al.
Publicado: (2015)

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
por: Iida, K, et al.
Publicado: (2011)

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
por: Scartozzi, M, et al.
Publicado: (2007)

Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy
por: Negri, F V, et al.
Publicado: (2008)

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)

Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma
por: Keller, J, et al.
Publicado: (2013)

Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM
por: Bryan, R T, et al.
Publicado: (2015)

Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
por: Cihoric, N, et al.
Publicado: (2014)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_3k77o3hsab0og388orhc6dlhor